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Abstract
Epithelial-to-mesenchymal transition (EMT) plays a critical role in cancer metastasis, and is
regulated by growth factors such as transforming growth factor β (TGF-β) and fibroblast
growth factors (FGF) secreted from the stromal and tumor cells. However, the role of growth
factors in EMT has not been fully established. Several integrins are upregulated by TGF-β1
during EMT. Integrins are involved in growth factor signaling through integrin-growth factor
receptor crosstalk. We previously reported that FGF1 directly binds to integrin αvβ3 and the
interaction was required for FGF1 functions such as cell proliferation and migration. We
studied the role of αvβ3 induced by TGF-β on TGF-β-induced EMT. Here, we describe that
FGF1 augmented EMT induced by TGF-β1 in MCF10A and MCF12A mammary epithelial
cells. TGF-β1 markedly amplified integrin αvβ3 and FGFR1 (but not FGFR2). We studied if
the enhancing effect of FGF1 on TGF-β1-induced EMT requires enhanced levels of both
integrin αvβ3 expression and FGFR1. Knockdown of β3 suppressed the enhancement by
FGF1 of TGF-β1-induced EMT in MCF10A cells. Antagonists to FGFR suppressed the
enhancing effect of FGF1 on EMT. Integrin-binding defective FGF1 mutant did not augment
TGF-β1-induced EMT in MCF10A cells. These findings suggest that enhanced integrin
αvβ3 expression in addition to enhanced FGFR1 expression is critical for FGF1 to augment
TGF-β1-induced EMT in mammary epithelial cells.
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Introduction
Dynamic cross-regulation of growth factors is a hallmark of epithelial-mesenchymal transition
(EMT) [1–3]. Fibroblast growth factors (FGFs) control multiple biological processes such as
proliferation, survival, migration and differentiation of a variety of cell types [4, 5]. FGF signal-
ing also plays a role in EMT and morphogenesis of mesoderm in mice at gastrulation by con-
trolling Snail that inhibits E-cadherin expression [6]. Thus FGF signaling is necessary to
control a specification of mesodermal and endodermal fates through some of the genes
involved in the EMT during development [7].
Deregulation of FGF signaling in different types of cancer has been reported. In most cases FGF
signaling is overactivated by constitutively active mutations of FGF receptors, gene amplifications,
and autocrine and paracrine signaling [8]. Aberrant FGF signaling promotes tumor development
by directly regulating cancer cell proliferation, survival, and by promoting tumor angiogenesis [9].
FGF1 is a prototypic member of the FGF family, which has been implicated in a range of
physiological processes, including development; wound healing and cancer development [10].
Ectopic expression of FGF1 in bladder carcinoma cells induces a mesenchymal phenotype corre-
lated with the internalization of E-cadherin and the relocation of β-catenin from the cell mem-
brane to the cytoplasm and nucleus [11]. Stimulation of the bladder cells with FGF1 induces a set
of genes attributed to EMT induction and to proteolysis [12]. FGF1 reverts TGF-β1-induced
EMT in human and rat alveolar epithelial-like cell lines [13]. The role of FGF1 and the molecular
mechanisms by which FGF1-regulated EMT during cancer progression remain unsolved.
Integrins are a family of cell adhesion receptors that recognize extracellular matrix ligands,
cell surface molecules, and growth factors. Integrins are transmembrane α-β heterodimers, and
at least 18 α and 8 β subunits are known [14]. In addition to mediating cell adhesion, integrins
make transmembrane connections to the cytoskeleton and activate several intracellular signal-
ing pathways [15]. Integrin signaling and functions are dependent on crosstalk with other sig-
naling pathways, especially growth factor signaling pathways, since integrins possess no
enzymatic activity [16, 17]. Several integrins are upregulated by TGF-β1 during the EMT pro-
cess [18, 19]. It has been well established that integrins are involved in growth factor signaling
through integrin-growth factor receptor crosstalk. We have previously demonstrated that
FGF1 directly interacts with integrin αvβ3 and induces the FGF1-FGF receptor (FGFR)-integ-
rin αvβ3 ternary complex formation [20–22]. This interaction is necessary for FGF1 functions
including cell proliferation, migration and angiogenesis [20–22].
TGF-β1 induces integrin αvβ3 expression and the enhanced expression of αvβ3 potentiates
TGF-β1-induced responses in lung fibroblasts [23, 24]. Also, integrin αvβ3 enhances TGF-β path-
way through TβR-II activation and enhances EMT in mammary epithelial cells [25]. Furthermore,
integrin αvβ3 induces metastatic phenotype in hepatocellular carcinoma by enhancing TGF-β1 sig-
naling [26]. However, the precise role of αvβ3 in TGF-β1-induced EMT has not been established.
In this study we studied the effect of FGF on TGF-β-induced EMT in mammary epithelial cells.
In this model TGF-β induces αvβ3 and FGF1 enhanced TGF-β-EMT.We demonstrate that direct
binding of FGF1 to αvβ3 is required for the enhancing effect of FGF1 on TGF-β-induced EMT. So
the enhanced expression of αvβ3 is a critical component in the enhancing effect of FGF1 on TGF-
β-induced EMT. This represents a newmodel of growth factor-integrin crosstalk in EMT.
Materials and Methods
Cell Culture and Treatments
MCF10A and MCF12A human mammary epithelial cell line, SK-BR-3 and ZR-75-30 breast
cancer cell lines were obtained from American Type Culture Collection (ATCC). MCF10A and
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MCF12A cells were cultured in DMEM/F-12 containing 5% horse serum, 100 U/ml penicillin,
100 μg/ml streptomycin, and 10 μg/ml insulin, 20 ng/ml EGF, 1 ng/ml cholera toxin, 100 μg/ml
hydrocortisone [27]. SK-BR-3 cells stably knockdown integrin β3 and ZR-75-30 cells that sta-
bly express integrin β3 were cultured in DMEM and RPMI-1640, respectively, and supple-
mented with 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin.
Experiments were performed when cells reached 50 to 60% confluence. Recombinant human
TGF-β1 was purchased from PeproTech (Rocky Hill, NJ) and reconstituted in water according
to the manufacturer's instructions. Wild-type FGF1 (WT) and mutant form FGF1 (R50E) were
bacterially expressed and purified as described previously [20]. FGFR inhibitor PD173074 and
MEK inhibitor U0126 were purchased fromWako pure chemicals (Osaka, Japan) and dis-
solved in Me2SO (DMSO). To induce EMT, cells were starved for 8 to 16 h then stimulated
with 5 ng/ml TGF-β1 in serum-free medium and/or 50 ng/ml recombinant human FGF1 (WT
or R50E) plus heparin (10 μg/ml) and additionally incubated for 48hous.
Transient and Stable Transfection of Integrin β3
For transient gene silencing experiments, Mission siRNA oligonucleotides (Sigma) for the
human integrin β3 (catalog no. SASI_Hs01_00174219 and SASI_Hs01_00174221) were used.
Mission siRNA universal negative control (Sigma) was used as a negative control. The siRNAs,
30 nM final concentration of each siRNA duplex, were transfected into MCF10A cells using
the lipofectoamine RNAiMAX (Invitrogen) according to the manufacturer's instructions. After
a 48 h gene silencing for Integrin αv and β3, respectively, both target gene and control siRNA-
treated cells were harvested and applied for Western blotting or flow cytometry.
Stably transfectable anti-integrin β3 short hairpin RNA plasmid was generated as follows.
We synthesized oligodeoxyribonucleotide chosen from The RNAi Consortium (TRC) shRNA
library (Broad Institute) for integrin β3 (Clone ID. TRCN0000003236). The shRNA segment
was subcloned downstream of the human U6 promoter between restriction sites AgeI and
EcoRI in the pLKO.1-TRC cloning vector (Addgene), which contains puromycin resistance
marker. The scramble shRNA (Addgene) were used as negative control.
For stable transfection of integrin β3, pcDNA3.1-β3 (Addgene) that contains neomycin
resistance marker was used. Empty pcDNA3.1 vector was used as a negative control. The plas-
mids were transfected into SK-BR-3 cells for knock-down or ZR-75-30 cells for overexpressing
using lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions and
selected successful integration by puromycin or G418 for 10 days. For generation of clonal sta-
ble cell lines, single colonies were chosen and propagated in the presence of puromycin or
G418 containing media, and expression of integrin β3 was confirmed by Western blotting and
dimerization of integrin αv and β3 in ZR-75-30 cells was confirmed by flow cytometry using
antibody LM609 that is specific to αvβ3 heterodimer.
Three-Dimensional Culture Assays-MCF10A Cells Form Acini when
Cultured on Matrigel In Vitro
The constitute cells can establish apicobasal polarity and form a hollow sphere [28, 29].
MCF10A cells were seeded on glass cover slip coated with growth factor–reduced Matrigel (BD
Biosciences), as described [27]. Cells were cultured in assay medium (DMEM/F12 supple-
mented with 2% horse serum, 10 μg/mL insulin, 1 ng/mL cholera toxin, 100 μg/mL hydrocorti-
sone, 50 units/mL penicillin and 50 μg/mL streptomycin) containing 5 ng/mL EGF and 2%
growth factor-reduced Matrigel. Medium was changed every 4 days. After 2 weeks of incuba-
tion, acinar structures were formed on the Matrigel. Assay medium was replaces to DMEM/
F12 containing 2% horse serum and 2% growth factor-reduced Matrigel. Then EMT was
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induced by 5 ng/ml TGF-β1 and 50 ng/ml recombinant human FGF1 (WT or R50E) for 4
days. The medium was changed once during period of stimulation.
Western Blotting
Cells were lysed in lysis buffer (10 mM Tris-HCl pH 7.5, 150 mMNaCl, 1 mM EDTA, 0.5%
NP-40, protease inhibitor cocktail and phosphatase inhibitor cocktail (Nacalai, Kyoto, Japan)).
Samples were resolved by SDS-PAGE and transferred to a polyvinylidene difluoride membrane
(Millipore, Billerica, MA). The blots were proved with primary antibodies and horseradish per-
oxidase conjugated secondary antibodies (GE healthcare, Piscataway, NJ), and then visualized
by enhanced chemiluminescence reagent (Pierce, Rockford, IL). Antibodies used for Western
blotting were as follows. Rabbit anti-N-cadherin (YS) was Immuno-Biological Laboratories
(Gunma, Japan); mouse anti-E-cadherin (4A2C7) was Invitrogen (Carlsbad, CA); rabbit anti-
ERK1/2 (137F5), rabbit anti-phospho ERK1/2 (D13.14.4E), rabbit anti-phospho Smad2,
mouse anti-MMP9 (D603H), mouse anti-PAI-1 (D9C4) were from Cell Signaling Technology
(Danvers, MA); rabbit anti-FGFR1 (C-15), mouse anti-integrin β3 (SAP), mouse-integrin αV
(P2W7), mouse anti-GAPDH (0411) were from Santa Cruz Biotechnology (Santa Cruz, CA);
rabbit anti- FGFR2 was from Sigma; mouse anti-MMP2 (42-5D11) was from Daiichi fine
chemical (Toyama, Japan). Densitometric analysis of Western blots was performed using Ima-
geJ software (http://rsb.info.nih.gov/ij/index.html).
Reverse Transcription Quantitative Real-Time PCR
Total RNA was isolated using Sepasol (Nacalai, Kyoto, Japan), cDNA was synthesized using AMV
Reverse Transcriptase (Promega, Madison, WI) and subsequent quantitative real-time PCR
was done in a Roche LightCycler-480 using SYBR Green Master Mix (Roche, Indianapolis, IN)
according to manufacturer’s instructions. Expressions were quantified using the following
primers: N-cadherin 5’-CCATCACTCGGCTTAATGGT-3’ and 5’-ACCCACAATCCTGTCC
ACAT-3’ and vimentin 5’-GCCCTTAAAGGAACCAATG-3’ and 5’-CCTTCCAGCAGCTTC
CTGTAG-3’, Snail1 5’- GGTTCTTCTGCGCTACTGCT-3’ and 5’- TAGGGCTGCTGGAAG
GTAAA-3’ and, Snail2 5’- GCGATGCCCAGTCTAGAAAA-3’ and 5’- GCAGTGAGGGCAA
GAAAAAG-3’. Relative quantification of cDNA amounts was done using the data analysis
function of the Roche Molecular Biochemicals Light Cycler Software (V. 3.5). Expression levels
were calculated in relation to the expression level of β-Actin and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) as the reference genes. The primers for β-Actin were 5’-CTCCTCC
CTGGAGAAGAGCTACGA- 3’ and 5’-ATGATGGAGTTGAAGGTAGTTTCG- 3’ and
GAPDH were 5’-CAATGACCCCTTCATTGACC-3’ and 5’-TTGATTTTGGAGGGATCTC
G-3’. For quantification using real-time reverse transcription-PCR, at least three independent
experiments with triplicate amplifications were performed.
Immunofluorescence
Cells were seeded and treated on coverslips. They were then fixed in 4% paraformaldehyde for
10 minutes, permeabilized with 0.5% Triton X-100 in PBS for 10 minutes, washed twice with
PBS, and blocked with 1% BSA in PBS for 1 hour, cells were incubated with primary antibodies
diluted in blocking buffer. Primary antibodies used for immunofluorescence as follows. Mouse
anti-integrin αvβ3 (LM609, Millipore), mouse anti-laminin-5 (D4B5, Millipore) and rat anti-
integrin α6 (GoH3, eBioscience). Secondary antibodies were donkey anti-mouse IgG FITC
conjugated (GE healthcare) and donkey anti-rat IgG FITC conjugated (GE healthcare). Cover-
slips were mounted in Prolong Gold with 40,6-diamidino-2-phenylindole (DAPI; Invitrogen).
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Fluorescence images were taken by Nikon Eclipse TE2000E fluorescence microscope (Nikon,
Tokyo, Japan) with digital camera.
Flow Cytometry
For flow cytometric detection of integrins, treated cells grown in culture dishes were harvested
with Trypsin/EDTA and washed with PBS. After incubation in a primary antibody in 1% BSA
in DMEM for 30 minutes at 4°C, the cells were washed with 1% BSA in DMEM. Primary anti-
bodies used in this assay were anti-integrin αvβ3 (LM609), anti-integrin β1 (SG19), anti-integ-
rin β3 (SAP), anti-integrin α2 (P1E6, Millipore), anti-integrin α3 (P1B5, Santa Cruz
Biotechnology), anti-integrin α4 (SG73), anti-integrin α5 (KH72), anti-integrin α6 (GoH3)
and anti-integrin α9β1 (Y9A2, Santa Cruz Biotechnology). Then cells were incubated in FITC
conjugated secondary antibody in 1% BSA in DMEM. Fluorescence-activated cell sorting
(FACS) analysis (FACS Calibur, Becton Dickinson, San Jose, CA) was done after additional
washes in PBS at 4°C.
Invasion Assay
Invasion assays were done in Chemotaxicell inserts (Kurabo, Osaka, Japan) with 8 μm polycar-
bonate filters coated with 100 μg/ml Growth factor reduced Matrigel for 3 h at 37°C and
blocked with 0.1% bovine serum albumin in PBS. Cells were suspended in serum-free DMEM/
F12 containing 0.1% BSA at a concentration of 105 cells in 200 μl and seeded in the upper
chamber. The lower chamber was filled with 500 μl DMEM/F12 containing 0.1% BSA and
5 ng/ml TGF-β1 and/or 50 ng/ml recombinant human FGF1. Then, cells were allowed to
migrate for 24 h. The upper side of the filters was wiped with cotton swabs, fixed, and stained
with 0.1% crystal violet. Images were taken by digital camera and counted using cell counting
function of Image J software.
Gelatin Zymography
Conditioned media were collected and concentrated using a Centricon (Millipore, Bedford,
MA). Gelatinolytic activities were detected in SDS-polyacrylamide gels containing 2 mg/ml gel-
atin. After electrophoresis, SDS was removed by incubating the gel with 2.5% Triton X-100 and
gelatinase activity was revealed by overnight incubation at 37°C with incubation buffer con-
taining 50 mM Tris-HCl pH 6.8, 5 mM CaCl2, 1 μM ZnCl2. Then the gel was stained with Coo-
massie Brilliant Blue.
In Vitro Wound Healing Assay
Cells were allowed to grow in the culture medium for overnight in cell culture dishes. Then
cells were washed with serum-free medium and starved for 8 h, and treated with 5 ng/ml
TGF-β1 and/or 50 ng/ml recombinant human FGF1 (WT or R50E) to induce EMT for 24 h.
A scratch was made across the cell layer using a pipette tip. After washing with serum-free
medium twice, cells were incubated in same conditioned as above for additional 24 h. Images
were observed using phase-contrast inverted microscope (Olympus, Tokyo, Japan) with digital
camera and the wounded areas were quantified by using ImageJ.
Statistical Analysis
Results are presented as the mean ± S.E. of at least three independent experiments. Significant
differences were defined as p< 0.05.
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Results
FGF1 Enhances TGF-β1-Induced EMT in Mammary Epithelial Cells
We studied the effect of FGF1 on TGF-β1-induced EMT in MCF10A human mammary epithe-
lial cells. Serum-starved MCF10A cells were incubated for 48 h in serum-free medium contain-
ing TGF-β1 with or without 50 ng/ml FGF1. EMT markers, N-cadherin, PAI-1 and vimentin
levels were upregulated by TGF-β1 in MCF10A cells. Interestingly, combined stimulation of
TGF-β1 plus FGF1 enhanced the protein and mRNA levels of these proteins (Fig 1A and 1B).
Despite E-cadherin is one of the markers of EMT, we did not detect the obvious E-cadherin
downregulation by TGF-β1 in this condition (Fig 1A). This is not surprising since 1) not all cell
lines that have undergone EMT concomitantly lose E-cadherin expression [30], and 2) the E-
cadherin expression is not sufficiently suppressed by TGF-β1 within 48 h TGF-β1 stimulation
[31, 32].
It has been reported that TGF receptor and other tyrosine kinase receptors activate extracel-
lular signal-regulated kinase (ERK) [33, 34]. TGF-β1 activated-ERK phosphorylation was also
enhanced by FGF1 (Fig 1A). When FGF1 was added after 24 h TGF-β stimulation, we still
observed synergistic effects on N-cadherin level and ERK phosphorylation (data not shown).
This suggests that the effect of FGF1 on TGF-β-induced EMT is not specific to 48 h incubation
time.
We tested the effect of FGF1 on MMP2 and MMP9, target genes of TGF-β1. MMP9 was
amplified by combined stimulation of TGF-β1 and 50 ng/ml FGF1, while no significant change
was detected in MMP2 expression (Fig 1C).
EMT is also characterized by increased cell motility and invasiveness, key events in cancer
metastasis [35]. We examined whether FGF1 regulates TGF-β1 induced cell invasion.
MCF10A cells were cultured on Matrigel coated trans-well chamber for 24 h and invaded cells
were counted. FGF1 enhanced the invasion of MCF10A cells into Matrigel when cells were
treated with TGF-β1 (Fig 1D). Furthermore, consistent with the result of the invasion assay,
TGF-β -induced MMP2 secretion was upregulated by FGF1 in gelatin zymography (Fig 1E).
We used another normal mammary epithelial cell line, MCF12A, was used to study if the effect
of FGF1 on TGF-β1-induced EMT is cell-specific. We obtained very similar results: N-cadherin
and phosphorylated ERK were upregulated by combination of FGF1 plus TGF-β1 (Fig 1F),
suggesting that the effect of FGF1 on TGF-β1-induced EMT is not cell-specific. To rule out the
effect of FGF1 is due to its effect on cell proliferation, we counted the cell number after 48 h
stimulation with FGF, TGF-β, or FGF plus TGF-β. There was no difference among the cell
numbers (data not shown), suggesting that the observed affects were not due to FGF1’s effect
on cell proliferation.
Integrin αvβ3 Is Markedly Upregulated by TGF-β1
We have previously reported that FGF1, integrin αvβ3 and FGFR1 ternary complex formation
is critical for FGF signaling such as motility, cell proliferation, and angiogenesis [20, 21]. Integ-
rin αvβ3 is induced by TGF-β1 in lung fibroblast cells and murine mammary gland cells [23,
25]. Hence, we reasoned that the enhancement effect of FGF1 is due to increased integrin αvβ3
levels.
To address this question, we first studied which integrins are induced by TGF-β1 in
MCF10A cells. FACS analysis revealed that integrin αvβ3 was the only integrin induced by
TGF-β1 among tested integrins (Fig 2A). We next determined the levels of integrin αvβ3
expressions by Western blotting. TGF-β1 quickly and strongly induced integrin αvβ3 (Fig 2B).
We also studied the time-course of TGF- β signaling. Interestingly, 5 ng/ml TGF-β1 induced
FGF1, Integrin αvβ3, and TGF-β-Induced EMT
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both canonical Smad pathway and non-canonical MAP kinase pathway. Smad2 phosphoryla-
tion peaked at 3 h and gradually decreased until 48 h, while phosphorylated ERK peaked at
48 h after TGF-β1 stimulation (Fig 2B). Integrin αvβ3 expression on the cell surface was
assessed by flow cytometer using anti-integrin αvβ3 antibody (LM609). Integrin αvβ3 was
induced by TGF-β1 dose-dependently in MCF10A cells (Fig 2C). Similar results were obtained
by immuno-staining analysis. Integrin αvβ3 was localized to plasma membrane, and the level
of integrin αvβ3 was much increased by TGF-β1 (Fig 2D). To clarify the morphological
changes of the EMT by the TGF, we included phase contrast images in Fig 2D lower panel.
These results suggest that TGF-β1 markedly induces αvβ3 in MCF10A cells.
Integrin αvβ3 Is Required for FGF1 to Enhance TGF-β1-Induced EMT
FGF1 directly interacts with integrin αvβ3 and induces the FGF1-FGF receptor (FGFR)-integ-
rin αvβ3 ternary complex formation, which is necessary for FGF1 functions [20–22]. Gene
silencing experiments of integrin β3 were performed to test the role of integrin αvβ3 on FGF1
and TGF-β1-inducing cell motility. Integrin β3 specific siRNAs effectively suppressed the gene
expressions and suppressed TGF-β1-induced N-cadherin expression, but no change was
observed in control siRNA (Fig 3A). The knockdown of integrin β3 decreased the effect of
FGF1 on TGF-β1-induced cell motility to baseline (Fig 3B). These results suggest that αvβ3 is
required for mediating FGF1 function in TGF-β1-induced EMT.
To confirm the importance of integrin αvβ3 to mediate FGF1 signaling in cancer cells, we
establish stably knockdown of integrin β3 into SK-BR-3-breast cancer cells, in which αvβ3 is
moderately expressed. Consistent with transient knock down of integrin β3 in MCF10A, its sta-
ble knockdown in SK-BR-3 cells suppressed FGF1-induced N-cadherin expression and the cell
motility (Fig 3C and 3D). We overexpressed αvβ3 in ZR-75-30 cells, which hardly express
αvβ3. Overexpression of αvβ3 in ZR-75-30 cells increased FGF1-induced N-cadherin expres-
sion (Fig 3E).
These results suggest that αvβ3 is required for FGF1 function in TGF-β1-induced EMT.
Direct Interaction between FGF1 and Integrin αvβ3 Is Necessary for the
Effect of FGF1 on EMT
We have reported that an integrin-binding defective FGF1 mutant (Arg-50 to Glu, R50E) is
defective in signaling functions [20]. We evaluated the role of direct binding of FGF1 to integ-
rin αvβ3 in TGF-β1-induced EMT using R50E. MCF10A cells were treated with TGF-β1 in the
absence or presence of WT-FGF1 or R50E. R50E did not increase N-cadherin, phosphorylated
Smad2 and phosphorylated ERK1/2 levels induced by 5 ng/ml TGF-β1 (Fig 4A). Interestingly,
FGF1 enhanced TGF-β1-mediated Smad2 phosphorylation. FGF1 alone does not induce
Smad2 phosphorylation. If integrin αvβ3 is induced by TGF-β, FGF1 signaling is coupled to
αvβ3 signals and may increase Smad2 signaling.
Fig 1. FGF1 amplifies TGFβ-1-induced EMT in mammary epithelial cells. Starved MCF10A cells were treated with or without 5 ng/ml TGF-β1 in the
absence or presence of 50 ng/ml FGF1 for 48 h. A, Cell lysates were applied for Western blotting with the indicated antibodies. GAPDH and total ERK1/2
were used as a loading control. B, Total RNA was extracted and revers transcribed to cDNA. N-cadherin and vimentin, Snail1 and Snail2 expressions were
assessed by real-time RT-PCR.C, Cell lysates were applied for Western blotting with the indicated antibodies.D, Matrigel invasion assay was performed on
MCF10A cells following treatment with 5 ng/ml TGF-β1 in the presence or absence of FGF1. E, Conditioned media were applied for gelatin zymography and
MMP2 activity were assessed by gelatin digestion in the gel. F, MCF12A cells were starved and treated with or without 5 ng/ml TGF-β1 in the absence or
presence of 50 ng/ml FGF1 for 48 h. Western blotting was performed with the indicated antibodies. Data represent the mean ± S.E. (n = 3; *, p < 0.05). Bands
intensity was measured by densitometry.
doi:10.1371/journal.pone.0137486.g001
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Fig 2. Integrin αvβ3 and FGFR1 are induced by TGF-β1 in MCF10A cells. A, Starved MCF10A cells were stimulated with or without 5 ng/ml TGF-β1 for 48
h. Cell surface expression of integrins were determined by FACS analysis using indicated antibodies. B, We performed time-course analysis of FGFR1,
FGFR2, and integrin αv and β3 expression byWestern blotting. Starved MCF10A cells were stimulated with DMSO or TGF-β1 (5 ng/ml) for the indicated time
periods. Cell lysates were applied for Western blotting and proved with antibodies shown in figure. GAPDH was used as loading control.C, Dose-dependent
effect of TGF-β1 on integrin αvβ3 was assessed by FACS flow cytometry. MCF10A cells were treated with the indicated concentration of TGF-β1. D,
Induction of integrin αvβ3 was determined by immunofluorescence microscopy. Cells were stimulated with TGF-β1 (0.5 or 5 ng/ml) for 48 h, and stained with
anti-integrin αvβ3 antibody (LM609) with FITC conjugated secondary antibody to visualize (upper). Lower panels indicate representative phase contrast
images of TGF-β1 stimulated cells. Scale bar = 20 μm.
doi:10.1371/journal.pone.0137486.g002
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Fig 3. Integrin αvβ3 is required for FGF1 to amplify TGF-β1-induced EMT. A, MCF10A cells were transfected with siRNA designed to target integrin β3
(si β3#1 and si β3#2). Non-targeting scramble siRNA (scr) is also transfected as a control. 24h post-transfection, cells were treated with 5 ng/ml TGF-β1 in
the absence or presence of FGF1 (50 ng/ml) for 48h. Cells were then lysed, and protein levels were analyzed byWestern blotting and probed with the
indicated antibodies. B, MCF10A cells were transfected and treated same as above, confluent cells were then scratched by pipet tip, which allowed cells to
migrate to the open space and cultured for additional 24h. Graph shows the fold change of closed wound area after 24 h. C, SK-BR-3 breast cancer cells
stably transfected with shRNA for either integrin β3 (sh β3#5 and sh β3#12) or non-targeting scramble shRNA (scr), then cells were stimulated with 50 ng/ml
FGF1 for 24h. Protein levels were determined byWestern blotting with the indicated antibodies. D, SK-BR-3 cells were transfected and treated same as
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Wound healing assay also demonstrated that R50E did not show any effect on wound heal-
ing increased by TGF-β1 (Fig 4B). These findings suggest that the direct biding of FGF1 to
integrin αvβ3 is crucial to the function of FGF1 to enhance TGF-β1-induced EMT.
TGF-β1-Induced Loss of Polarity in 3D Culture of MCF10A Is Regulated
by the Interaction between FGF1 and Integrin αvβ3
Several oncogenes and excessive growth factors lead to disrupted mammary cell polarity in 3D
sphere models [36]. We tested the functional roles of interaction between FGF1 and integrin
αvβ3 in epithelial polarity using 3D culture of MCF10A cells. MCF10A cells were cultured on
Matrigel to form acinus structure for 10 days, and then TGF-β1, FGF1, or both are added to
the culture for additional 10 days. Immunofluorescence staining showed that integrin αvβ3
was not detected in non-treated MCF10A cells that form morphologically normal mammary
acini with central lumen. When the cells were treated with 5 ng/ml of TGF-β1, integrin αvβ3
expression was induced mainly in cytosol, and the polarized organization was disturbed with
cell-filled lumen (Fig 5A upper panels). FGF1 increased TGF-β1-induced depolarization of aci-
nus structure at TGF-β1 (Fig 5A middle panels). However, R50E did not alter TGF-β1-induced
depolarization (Fig 5A lower panels). Apicobasal polarization was detected by immunostaining
for the α6 integrin as a basal marker. As observed above, R50E did not alter TGF-β1-induced
depolarization (Fig 5B). We counted acini with a discontinuous basement membrane, namely
collapsing polarized structure, based on integrin α6 expression against multiple acini in each
condition (Fig 5C). We conclude that FGF1 enhances TGF-β-induced depolarization of acini
structure. Thus, direct interaction between FGF1 and integrin αvβ3 is required to exert amplifi-
cation effects of FGF1 on TGF-β1-induced EMT in MCF10A acinar structure.
ERK Activation Is Required for Enhancement of TGF-β1-Induced EMT
by FGF1
We found that FGFR1 is up regulated by TGF-β but not FGFR2. These findings are consistent
with the previous report [37]. PD173074, a selective inhibitor for FGFR, suppressed the effect
of FGF1 on N-cadherin expression and ERK1/2 activation increased by TGF-β1 (Fig 6A, lane
8), suggesting that FGFR1 is necessary for enhancing effect of FGF1 on the N-cadherin level
and ERK activation.
It is well known that FGF1 and TGF-β1 induce activation of the MAPK-signaling pathway
in many cell types [33, 34]. To test if the MAPK pathway is involved in the effect of FGF1 on
the TGF-β1-induced EMT, we treated MCF10A cells with U0126, a selective inhibitor for
MAPK extracellular signaling-regulated kinase (ERK) kinase (MEK). The effect of FGF1 on N-
cadherin expression and activation of ERK were significantly inhibited by U0126 (Fig 6B, lanes
8), indicating that the MAPK pathway is critical to transduce synergistic effect of FGF1 and
TGF-β1 on EMT. Interestingly, TGF-β1-induced N-cadherin expression was suppressed by
U0126 (Fig 6B, lanes 6), suggesting that TGF-β1-induced N-cadherin expression may depend
mainly on MAPK pathway in MCF10A cells.
above, confluent cells were scratched and cultured for additional 24h. Graph shows the fold change of closed wound area after 24 h. E, ZR-75-30 breast
cancer cells were stably transfected with integrin β3 expression vector or empty vector as a control, then cells were stimulated same as C. Protein levels
were determined byWestern blotting with the indicated antibodies. Data represent the mean ± S.E. (n = 3; *, p < 0.05). Bands intensity was measured by
densitometry.
doi:10.1371/journal.pone.0137486.g003
FGF1, Integrin αvβ3, and TGF-β-Induced EMT
PLOSONE | DOI:10.1371/journal.pone.0137486 September 3, 2015 11 / 18
Fig 4. Integrin binding defective FGF1mutant R50E is not able to enhance EMT. A, Starved MCF10A
cells were treated with 5 ng/ml TGF-β1 in the presence of 50 ng/ml WT-FGF1 (WT) or integrin binding
defective FGF1 mutant (R50E) for 48 h. Cell lysates were processed for Western blotting with the indicated
antibodies. ERK1/2 and GAPDH served as a loading control. B, Starved MCF10A cells were treated with 5
ng/ml TGF-β1 in the presence of 50 ng/ml WT-FGF1 (WT) or integrin binding defective FGF1 mutant (R50E)
for 24 h. Confluent cell monolayer was scratched by pipet tip and cultured additional 24 h in same conditions.
Images were taken by phase-contrast microscopy and measured area of wound closure. Data represent the
mean ± S.E. (n = 3; *, p < 0.05, **, p < 0.01). Bands intensity was measured by densitometry.
doi:10.1371/journal.pone.0137486.g004
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Discussion
It has long been believed that integrins bind to extracellular matrix proteins, and growth factor
receptors bind to growth factors, and the two separate signals are linked to one another in mul-
tiple steps in the pathway [17, 38, 39]. In contrast to this model, we reported that FGF1 directly
binds to integrin αvβ3 and induces the FGFR1-FGF1-integrin αvβ3 ternary complex, and the
interaction increases fibroblast and endothelial cell growth and motility [20, 22].
Fig 5. FGF1 augments TGF-β1-induced loss of polarity depends on the interaction between FGF1 and integrin αvβ3. A and B, MCF10A cells were
seeded on glass cover slip coated with growth factor-reduced Matrigel. After 2 weeks of incubation, acinar structures were formed on the Matrigel. Assay
medium was replaces to DMEM/F12 containing 2% horse serum and 2% growth factor-reduced Matrigel. Then cells were treated for inducting EMT with 5
ng/ml TGF-β1 together with either 50 ng/ml WT-FGF1 (WT) or integrin binding defective FGF1 mutant (R50E) for 4 days. The acini were immunostained with
an anti-integrin αvβ3 (A, green) or an anti-integrin α6 (B, green) antibody together with DAPI labels nuclei (blue). Confocal images were acquired at the center
plane of the acinar structure. Scale bar = 50 μm. C, MCF10A cells were treated as in A, then acini indicating discontinuous basement membrane was
counted from the images.
doi:10.1371/journal.pone.0137486.g005
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The present study demonstrated that TGF-β1 markedly induced integrin αvβ3 expression,
and blocking integrin αvβ3 by RNAi abrogated FGF1- and TGF-β1-induced wound healing in
MCF10A cells as well as in a breast cancer cell line that naturally expresses moderate level of
integrin αvβ3. Thus, our findings suggest that integrin αvβ3 expression induced by TGF-β1 is
required for enhanced EMT in mammary epithelial cells. Particularly, we showed that direct
integrin interaction with FGF1 is involved in the increasing effect of FGF-1 on TGF-β1 signal-
ing. Also, TGF-β1 induced FGFR1 expression, consistent with a report [37]. A specific inhibi-
tor for FGFRs suppressed the enhancing effect of FGF1 on ERK activation and N-cadherin
Fig 6. FGFR and ERK signaling is required for FGF1 to mediate TGF-β1 induced EMT in MCF10A cells.
A and B, Starved MCF10A cells were stimulated with 5 ng/ml TGF-β1 and 50 ng/ml FGF1 in the presence of
1 μMPD173074 specific inhibitor of FGFR1 (A) or 10 μMU0126 specific inhibitor of MEK1 (B) for 48 h.
DMSOwas used as a solvent control for the chemicals. Cells were then lysed, and protein levels were
analyzed byWestern blotting with the indicated antibodies. Bands intensity was measured by densitometry.
doi:10.1371/journal.pone.0137486.g006
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expression. These observations suggest that expression of αvβ3 and FGFR1 is required for the
effect of FGF1 on TGF-β1-induced EMT.
Consistently, the integrin binding defective FGF1 mutant, R50E, did not augment TGF-
β1-induced morphological change, N-cadherin expression and cell motility in MCF10A cells.
Thus, the direct binding FGF1 to integrin αvβ3 is important for upregulation of EMT. Thus
αvβ3 acts as a co-receptor of FGF1 and that FGF1 induces αvβ3-FGF1-FGF1 ternary complex
formation [20, 21] in TGF-β1-induced EMT. If αvβ3 expression is not sufficient for FGF1 sig-
naling, it is expected that FGF1 signaling is deficient. In our preliminary studies, αvβ3 expres-
sion was not enhanced when TGF-β1 was used at low concentrations (0.5 ng/ml) in MCF-10A
cells. We observed that exogenous FGF1 did not enhance EMT, but rather suppressed it (data
not shown). This underscores the important role of αvβ3 in FGF signaling. Also, R50E appears
to antagonize TGF-β signaling. It is possible that FGF1 is required for TGF-β signaling, and
R50E may inhibit it. Since FGF1 (and R50E) bind to all of FGF receptor family members and
R50E may inhibit possible contribution of other FGF family members to TGF- β signaling. Fur-
ther studies are needed to address this hypothesis.
The MAP kinase cascade is major signaling pathway involved in FGFR and integrin medi-
ated cell fate. We found that the combination of FGF and TGF-β1 treatment resulted in more
robust ERK activation compared to TGF-β1 alone or FGF1 alone. The MEK inhibitor blocked
the activation of ERK signaling and upregulation of N-cadherin protein level caused by TGF-
β1 and FGF1 combination. Similarly to the observation, TGF-β1 and EGF-induced EMT
requires MAP kinase pathway, but not PI3K, p38, JNK or AP-1 pathway [40]. Our results show
that stimulation with TGF-β only induced ERK activity. Several reports suggest the possibilities
that TGF-β1 may induce autocrine FGF signaling [41], which can be inhibited by the FGFR
inhibitor, and directly activate downstream of FGFR [33]. This may explain why the effects of
specific inhibitor for FGFR were partial. Further studies of the crosstalk between TGF-β and
FGF signaling by other methods will be needed to address these observations.
Several groups report that growth factors such as EGF, PDGF, HB-EGF, and insulin-like
growth factor 1 (IGF1) increase TGF-β1-induced EMT in different cell lines [40, 42, 43]. These
support our finding that synergistic effect of FGF1 and TGF-β1 on EMT. We recently reported
that IGF1 signaling requires direct IGF1 binding to integrins such as αvβ3 [44–47] as in the
case of FGF1. We propose that increased αvβ3 expression induced by TGF-β1 also plays a role
in the enhancing effect of IGF1 on TGF-β1-induced EMT. On the other hand, vascular endo-
thelial growth factor (VEGF), hepatocyte growth factor (HGF) and FGF suppress TGF-
β1-induced EMT in kidney cortex cells and alveolar epithelial-like cells [13, 48–50]. Thus, it is
unclear how/why different growth factors induce opposite effects on TGF-β-induced EMT. In
the case of FGF, the levels of αvβ3 (and perhaps other integrins) might determine whether or
not FGF augments TGF-β-induced EMT, as described above. It would be interesting to study if
the levels of integrin expression and integrin expression profiles may be critical factors in the
effect of other growth factors on TGF-β-induced EMT in different cell lines in future studies.
In conclusion, the present study provides a new insight into the role of integrin αvβ3 in the
enhancing effect of FGF1 in TGF-β1-induced EMT. We provides evidence that direct FGF1
binding to integrin αvβ3 is critical for the enhancing effect of TGF-β1-induced EMT by FGF in
mammary epithelial cells.
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